News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-05-07 pm EDT			5-day change	1st Jan Change
44.04 ^USD	+0.32%		+0.23%	-14.17%

May. 07	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	MT
May. 06	Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Bristol Myers Squibb to Participate in Upcoming Investor Conferences	May. 07	BU
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	May. 06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	May. 06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	May. 06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...	May. 06	BU
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	May. 06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	May. 01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	Apr. 30
A flurry of corporate results ahead of the Fed's rate decision	Apr. 30
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb	Apr. 30	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
J&J, Bristol Myers lose challenges to US drug price negotiation program	Apr. 29	RE
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST